Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction
Part of paid clinical trials in Duarte, California.
- Sponsor
- National Cancer Institute (NCI)
- Study ID
- NCT01907802
- Phase
- PHASE1
- Status
- Terminated
Conditions
- BRAF Gene Mutation
- Hepatic Complication
- Renal Failure
- Solid Neoplasm
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Dabrafenib — DRUGGiven PO
- Laboratory Biomarker Analysis — OTHERCorrelative studies
- Pharmacogenomic Study — OTHERCorrelative studies
- Pharmacological Study — OTHERCorrelative studies
Study Details
This phase I trial studies the side effects and best dose of dabrafenib in treating patients with solid tumors and kidney or liver dysfunction. Dabrafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Key Dates
- Start date
- Aug 23, 2013
- Status verified
- Aug 2018
- Primary completion
- Dec 16, 2015
- Completion
- Dec 16, 2015
Study Design
- Enrollment
- 8 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment (dabrafenib)Patients receive dabrafenib PO BID on days 1-28 (QD on day 1 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Primary Outcome Measure
Incidence of toxicities graded according to NCI CTCAE v4.0 [ Time Frame: Up to 30 days after completion of study treatment ]
Locations (17)
Find similar trials in Duarte, CA
By research site
City of Hope Comprehensive Cancer Center· Duarte, CAUSC / Norris Comprehensive Cancer Center· Los Angeles, CAUniversity of California Davis Comprehensive Cancer Center· Sacramento, CACity of Hope South Pasadena· South Pasadena, CAUniversity of Colorado Hospital· Aurora, COMayo Clinic in Florida· Jacksonville, FL
Related Studies
- UWCCC Molecular Tumor Board RegistryRecruiting · University of Wisconsin, Madison · Madison, Wisconsin
- Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic MelanomaPHASE1 · Recruiting · Rina Plattner · Iowa City, Iowa
- Advancing Health Information Exchange (HIE) During Inter-hospital Transfer (IHT) to Improve Patient OutcomesEnrolling By Invitation · Brigham and Women's Hospital · Boston, Massachusetts
- Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive MalignanciesPHASE1/PHASE2 · Recruiting · Institut de Recherches Internationales Servier · Gilbert, Arizona